【摘要】：目的:觀察銀丹心腦通軟膠囊治療大動脈粥樣硬化性腦梗死恢復(fù)期瘀血阻絡(luò)證的臨床療效。方法:采用隨機(jī)、雙盲、陽性藥和安慰劑平行對照方法,將360例大動脈粥樣硬化性腦梗死恢復(fù)期的患者且辨證為瘀血阻絡(luò)證者隨機(jī)分成3組,分別服用銀丹心腦通軟膠囊、腦心通膠囊或安慰劑,用藥3個月并隨訪3個月。觀察用藥后患者生活能力、神經(jīng)功能缺損程度、殘障程度的變化,同時觀察藥物對動脈狹窄程度的影響,中醫(yī)證候改善的情況。結(jié)果:12周后,試驗組中Barthel指數(shù)≥75的病例顯著多于陽性藥組和安慰劑組(77.94%vs.63.57%vs.42.03%,P0.017);NIHSS量表評分較入組前降低≥5分患者比例也顯著多于陽性藥組和安慰劑組(63.97%vs.52.86%vs.24.64%,P0.017);有64.71%的病例達(dá)到無明顯殘障水平(改良Rankin量表0~2級),顯著高于安慰劑組(37.31%,P0.017),與陽性藥組比較無統(tǒng)計學(xué)意義(59.85%,P0.017);中醫(yī)證候總有效率為83.09%,顯著高于安慰劑組(57.97%,P0.017),與陽性藥組相當(dāng)(77.86%,P0.017);銀丹心腦通軟膠囊有改善頸動脈狹窄程度的趨勢,尚需進(jìn)一步驗證。結(jié)論:銀丹心腦通軟膠囊治療腦梗死后恢復(fù)期-瘀血阻絡(luò)證,能有效減輕患者中風(fēng)后的殘障程度、神經(jīng)功能缺損程度,改善中醫(yī)證候,提高患者生活質(zhì)量。
[Abstract]:Objective: to observe the clinical effect of Yindan Xinnaotong soft capsule (Yindan Xinnaotong soft capsule) on blood stasis and collaterals obstruction in convalescent stage of atherosclerotic cerebral infarction. Methods: 360 patients with atherosclerotic cerebral infarction in convalescence stage were randomly divided into 3 groups by randomized, double-blind, positive drug and placebo parallel control, and were treated with Yindan Xinnaotong soft capsule, respectively. Naoxintong capsule or placebo was used for 3 months and followed up for 3 months. The changes of the patients' living ability, the degree of nerve function defect and the degree of disability were observed. The influence of drugs on the degree of arterial stenosis and the improvement of TCM syndromes were observed at the same time. It turns out that 12 weeks later, The number of patients with Barthel index 鈮，

本文編號：2248794